Loading...
  • vivo
  • However, cytotoxic T cell-induced apoptosis, which is critically involved in tumor control in vivo, is not inhibited by cFLIP in vitro, as only CD95- and not perforin-dependent lysis is affected. (rupress.org)
  • Moreover, tumor cells are selected in vivo for elevated cFLIP expression. (rupress.org)
  • Transgenic expression of PD-L1, one of the PD-L, in P815 tumor cells rendered them less susceptible to the specific T cell antigen receptor-mediated lysis by cytotoxic T cells in vitro , and markedly enhanced their tumorigenesis and invasiveness in vivo in the syngeneic hosts as compared with the parental tumor cells that lacked endogenous PD-L. Both effects could be reversed by anti-PD-L1 Ab. (pnas.org)
  • Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. (springer.com)
  • The combination of shield and adapter also increases viral gene delivery to xenografted tumors in vivo, reduces liver off-targeting and immune neutralization. (ethz.ch)
  • macrophages
  • These positive feedback loops are generated by cytokines such as TGF-β, Interleukin-10 and Interleukin-4, which are responsible for the polarization of monocytes and M1 macrophages into pro-tumor M2 macrophages, and the polarization of naive helper T cells intopro-tumor Th2 cells. (scirp.org)
  • We identified combination therapies that consist of M1 macrophages or Th1 helper cells, coupled with an anti-angiogenic treatment, that are robust with respect to immune response strength, initial tumor size and treatment resistance. (scirp.org)
  • regression
  • Finally, linear regression modeling identifies major determinants of tumor immunogenicity, which include well-characterized modulators as well as a novel candidate, CCR8, which is then tested in an orthologous immunodeficient mouse model. (nih.gov)
  • Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. (springer.com)
  • single tumor
  • Personalis CSO, Richard Chen, MD, said, "With the integration of these additional capabilities, we're continuing to demonstrate our commitment to maximizing the biological insights that can be derived from single tumor samples, which are often limited in availability. (businesswire.com)
  • biomarker
  • Tumor PD-L1 expression is a potential efficacy biomarker, but the complex mechanisms underlying its regulation are not completely understood. (nature.com)
  • We're excited to be one of the first commercial providers of this analysis as part of ImmunoID NeXT™, the premier tumor immunogenomics platform for comprehensive biomarker evaluation in both solid and hematologic cancer indications. (businesswire.com)
  • malignant
  • PhD candidates within CANBIO will be engaged in a collaborative and interdisciplinary endeavour to deliver novel insight into tumour escape mechanisms, disease monitoring and large scale data analysis in highly malignant cancers. (crp-sante.lu)
  • specificity
  • We obtained comparable results with tumor-specific CTL clones that have a defined peptide specificity and Raji, a human Burkitt B cell lymphoma, loaded with the relevant peptide epitope as target cell (Medema, J.P., and J. de Jong, unpublished observations). (rupress.org)
  • novel
  • Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immun. (nih.gov)
  • murine
  • Survey of murine tumor lines revealed that all of the myeloma cell lines examined naturally expressed PD-L1. (pnas.org)
  • interactions
  • MENLO PARK, Calif.--( BUSINESS WIRE )--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of its universal cancer immunogenomics platform, ImmunoID NeXT , incorporating several additional features that are pivotal to the understanding of tumor and immune cell interactions and how the nature of these interactions can impact cancer patients' ability to respond to immunotherapies and combination therapies. (businesswire.com)
  • eradicate
  • Our results highlight the importance of immune cell reprogramming as a viable strategy to eradicate a highly vascularized tumor when the strength of the immune response is characteristically weak and cell polarization to the pro-tumor phenotype has occurred. (scirp.org)
  • Nonetheless, tumor-specific immune responses are normally very weak, if present at all, and not sufficient enough to eradicate the tumors. (pnas.org)
  • photodynamic
  • Initial tests in mouse models of pancreatic cancer found that intravenous delivery of the PMILs followed by localized delivery of near-infrared light to the tumor site via optical fibers resulted in significantly greater reduction in tumor size than did treatment with XL184 or photodynamic therapy with the photosensitizer BPD alone. (oncologynurseadvisor.com)
  • therapies
  • The new optically active nanoparticle we have developed is able both to achieve tumor photodamage and to suppress multiple escape pathways, opening new possibilities for synchronized multidrug combination therapies and tumor-focused drug release. (oncologynurseadvisor.com)
  • Vascular
  • Preclinical studies indicate that miR126, which is transcribed from intron 7 in the EGFL7 gene, is important for maintaining EC proliferation and migration, vascular integrity, VEGF-A signaling, and tumor growth ( 6-8 ). (aacrjournals.org)
  • Protein
  • Targeted protein toxins therefore have greatest potential for the treatment of residual disease and metastases in addition to surgically inaccessible, disseminated and hematopoietic tumors. (mdpi.com)